Although the main outcomes measured were symptoms of depression and negative cognitive biases, the study additionally aimed to investigate the impact of the CBM-I on trait anxiety.
Outcome measures were symptom scales (numbness, tingling, and autonomic symptoms), skin biopsies assessing epidermal nerve fiber density (ENFD), sweat gland nerve fiber density (SGNFD), and quantitative autonomic testing.
The selected outcome measures were: symptoms, adverse events of the treatments, lung function, airway responsiveness and inflammation.
Primary outcome measures were symptoms of depression and anxiety assessed before treatment and at follow-up using the Hopkins Symptom Checklist and the Mini-International Neuropsychiatric Interview.
Outcome measures were symptoms (pain, bothersomeness), functional status (Roland-Morris score), SF-12, worry, and difficulty performing 3 self-selected activities.
Secondary outcome measures were symptoms of depression and anxiety measured with the CES-D and HADS-A at baseline and at 3, 6, 9, 12, 18, and 24 months.
The primary outcome measure is symptom severity as measured by the Brief Symptom Inventory.
The primary outcome measure is symptom severity as measured by the Brief Symptom Inventory [ 37, 38].
The primary outcome measure is symptom severity as estimated by the self-rated Beck Depression Inventory (BDI).
Primary outcome measure was symptom scores, which were assessed and recorded on day 1, 3, 5, 7, 10.
